MTOR and prostate carcinoma: Recent advances in radiotherapy also indicate that triggering of the PI3K/AKT/mTOR pathway is closely relevant to radioresistance, which is a major challenge for current radiation treatment in prostate cancer (CaP) and other cancers (Heavey et al., 2014; Chang et al., 2015).